Implant Left Articles & Analysis: Older
6 news found
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces new data validating the benefits of the Company’s BVA-100 blood test (BVA) in improving survival for advanced heart failure patients with left ventricular assist device (LVAD). These data were presented at the International Society for Heart and Lung Transplant (ISHLT) ...
To regulate precise pacing from within the heart, WiSE uses a unique, wireless electrode the size of a grain of rice. It is implanted in the left ventricle wall during a minimally invasive procedure. ...
CorWave unveiled a groundbreaking study on the performance of its novel implantable left ventricular assist device (LVAD) at the ISHLT annual meeting, a leading event in the scientific community, which brings together the world's leading experts in the treatment of advanced heart and lung disease to improve patient care. CorWave is developing an ...
ByCorWave
CorWave, located in Clichy, Île-de-France, is developing an implantable heart pump (Left Ventricular Assist Device, LVAD) based on a breakthrough technology, the wave membrane pump. These new funds will enable CorWave to finalize the development of its product, build the manufacturing infrastructure as well as complete regulatory testing required to conduct ...
ByCorWave
Stage IIIB, locally advanced, ER/PR positive, HER-2 negative, grade 3, IDC of the left breast with muscle involvement diagnosed 07/30/2010, now with left lateral chest wall recurrence, ER/PR 100/100, strong/moderate, HER-2 negative, IDC involving the left lateral chest inferior and lateral to the axilla. ...
EBR Systems’ WiSE™ (Wireless Stimulation Endocardially) Technology paces the heart via a wireless electrode implanted directly in the left ventricle with an initial indication sought for heart failure patients who have failed to respond to or are unable to receive conventional cardiac resynchronization therapy. ...